ES2160649T3 - Nuevos compuestos lactamicos y procedimientos para su preparacion. - Google Patents

Nuevos compuestos lactamicos y procedimientos para su preparacion.

Info

Publication number
ES2160649T3
ES2160649T3 ES95109191T ES95109191T ES2160649T3 ES 2160649 T3 ES2160649 T3 ES 2160649T3 ES 95109191 T ES95109191 T ES 95109191T ES 95109191 T ES95109191 T ES 95109191T ES 2160649 T3 ES2160649 T3 ES 2160649T3
Authority
ES
Spain
Prior art keywords
procedures
preparation
compounds
new dairy
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95109191T
Other languages
English (en)
Inventor
Horst Dr Bohlke
Michael Dr Finkam
Oswald Dr Zimmer
Johannes Dr Schneider
Stephan Dr Wnendt
Kai Dr Zwingenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2160649T3 publication Critical patent/ES2160649T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cephalosporin Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE COMPUESTOS LACTAMO ELEGIDOS COMO SUSTANCIAS ACTIVAS FARMACEUTICAS, NUEVOS COMPUESTOS LACTAMO ASI COMO PROCESO PARA SU ELABORACION.
ES95109191T 1994-06-24 1995-06-14 Nuevos compuestos lactamicos y procedimientos para su preparacion. Expired - Lifetime ES2160649T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4422237A DE4422237A1 (de) 1994-06-24 1994-06-24 Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe

Publications (1)

Publication Number Publication Date
ES2160649T3 true ES2160649T3 (es) 2001-11-16

Family

ID=6521476

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95109191T Expired - Lifetime ES2160649T3 (es) 1994-06-24 1995-06-14 Nuevos compuestos lactamicos y procedimientos para su preparacion.

Country Status (13)

Country Link
US (1) US6500845B1 (es)
EP (1) EP0688771B1 (es)
JP (1) JPH0892092A (es)
AT (1) ATE203021T1 (es)
AU (1) AU689885B2 (es)
CA (1) CA2152432A1 (es)
DE (2) DE4422237A1 (es)
DK (1) DK0688771T3 (es)
ES (1) ES2160649T3 (es)
GR (1) GR3036532T3 (es)
HU (1) HUT72600A (es)
PT (1) PT688771E (es)
SI (1) SI0688771T1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE69739802D1 (de) * 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
ES2262753T3 (es) * 1997-11-18 2006-12-01 Celgene Corporation 2-(2.6-dioxo-3-fluorpiperidin-3-il)-isoindolinas substituidas y su empleo para reducir los niveles de tnfalfa.
ES2243052T3 (es) * 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
AU749356B2 (en) 1998-05-11 2002-06-27 Children's Medical Center Corporation Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
AU757272B2 (en) * 1999-05-20 2003-02-13 Eu Biotech Development Ltd Optically active quinoline carboxylic acid derivatives with 7-pyrrolidine substituents causing optical activity and a process for the preparation thereof
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
EP1389203B8 (en) * 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
CA2808646C (en) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
WO2007120669A1 (en) * 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
EA026100B1 (ru) 2011-03-11 2017-03-31 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705162A (en) * 1967-07-01 1972-12-05 Gruenenthal Chemie 4-phthalimidine glutarimides
DE3048663A1 (de) * 1980-12-23 1982-07-22 Grünenthal GmbH, 5190 Stolberg Neue lactamverbindungen, diese enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis

Also Published As

Publication number Publication date
EP0688771B1 (de) 2001-07-11
AU2323095A (en) 1996-01-11
HU9501801D0 (en) 1995-08-28
PT688771E (pt) 2001-11-30
EP0688771A1 (de) 1995-12-27
DE59509395D1 (de) 2001-08-16
SI0688771T1 (en) 2001-10-31
DK0688771T3 (da) 2001-09-17
AU689885B2 (en) 1998-04-09
DE4422237A1 (de) 1996-01-04
GR3036532T3 (en) 2001-12-31
JPH0892092A (ja) 1996-04-09
CA2152432A1 (en) 1995-12-25
ATE203021T1 (de) 2001-07-15
HK1010107A1 (en) 1999-06-11
US6500845B1 (en) 2002-12-31
HUT72600A (en) 1996-05-28

Similar Documents

Publication Publication Date Title
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
ES2162951T3 (es) Estabilizacion de composiciones de prostaglandina.
NO870241L (no) Hypoglykemiske tiazolidindioner.
SE8804629D0 (sv) New therapeutically active compounds
DE69123124D1 (de) Dihydro-Isoquinolinderivate
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
EP0605203A3 (en) Anti-allergic composition for ophthalmic or nasal use.
DE59108530D1 (de) Antimikrobielle Mittel sowie substituierte 2-Cyclohexan-1-yl-amin-Derivate und deren Herstellung
DK1224940T4 (da) Flydende formuleringer af interferon-beta
ES2181853T3 (es) Tratamiento del tinnitus empleando agentes neuroprotectores.
DK0409435T3 (da) Heteroarylpiperaziner som antipsykotiske midler
ATE212860T1 (de) Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
PT992509E (pt) Novos derivados macrolidos
ATE191142T1 (de) Verwendung von phenalkylaminen zur herstellung von cholesterinsenkenden arzneimitteln
BG106233A (en) Indole derivatives
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
EP0481299A3 (en) N-phenyl-piperidyl-4-amines and drugs containing them
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
SE9902387D0 (sv) New pharmaceutically active compounds
EP0302757A3 (en) Anti-emetic serotonin depleting agents
DK215886A (da) 1,3-oxathianderivater
DE69813165T2 (de) Hautdepigmentierungsmittel
JPS5513285A (en) Imidazoline compound and medical composition
FR2752420B1 (fr) Derives n-(alkyloxycarbonyl)-n-(2-hydroxy-3-alkyloxypropyl)- ethanolamine et leur utilisation dans et pour la preparation de compositions cosmetiques ou dermatologiques

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 688771

Country of ref document: ES